Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

被引：297

作者：

Kaufmann, M. ^{[1
]}

von Minckwitz, G. ^{[1
,2
]}

Bear, H. D. ^{[3
,4
]}

Buzdar, A. ^{[5
]}

McGale, P. ^{[6
]}

Bonnefoi, H. ^{[7
]}

Colleoni, M. ^{[8
]}

Denkert, C. ^{[9
]}

Eiermann, W. ^{[10
]}

Jackesz, R. ^{[11
]}

Makris, A. ^{[12
]}

Miller, W. ^{[13
]}

Pierga, J. -Y. ^{[14
]}

Semiglazov, V. ^{[15
]}

Schneeweiss, A. ^{[16
]}

Souchon, R. ^{[17
]}

Stearns, V. ^{[18
]}

Untch, M. ^{[19
]}

Loibl, S. ^{[1
,2
]}

机构：

[1] Goethe Univ Frankfurt, Frankfurt, Germany

[2] German Breast Grp, Frankfurt, Germany

[3] Virginia Commonwealth Univ, Div Surg Oncol, Massey Canc Ctr, Richmond, VA USA

[4] Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[6] Early Breast Canc Trialists Collaborat Grp, Oxford, England

[7] Hop Univ Geneve, EORTC Breast Canc Grp, Geneva, Switzerland

[8] Ist Europeo Oncol, Milan, Italy

[9] Charite, Inst Pathol, Berlin, Germany

[10] Krankenhaus Roten Kreuz, Frauenklin, Munich, Germany

[11] Univ Klin Chirurg, Vienna, Austria

[12] Mt Vemon Hosp, Northwood, Middx, England

[13] Univ Edinburgh, Western Gen Hosp, Edinburgh, Midlothian, Scotland

[14] Inst Curie, Dept Med Oncol, Paris, France

[15] NN Petrov Oncol Res Inst, St Petersburg, Russia

[16] Heidelberg Univ, D-6900 Heidelberg, Germany

[17] Allgemeines Krankenhaus Hagen, Hagen, Germany

[18] Johns Hopkins Univ, Sidney Kimmal Comprehens Canc Ctr, Baltimore, MD USA

[19] Helios Klinikum Berlin Buch, Berlin, Germany

来源：

ANNALS OF ONCOLOGY | 2007年 / 18卷 / 12期

关键词：

breast cancer; neoadjuvant therapy; recommendations; LYMPH-NODE BIOPSY; PATHOLOGICAL COMPLETE RESPONSE; INVASIVE LOBULAR CARCINOMA; GENE-EXPRESSION PROFILES; PREOPERATIVE CHEMOTHERAPY; RESIDUAL DISEASE; CYCLOPHOSPHAMIDE CHEMOTHERAPY; PHYSICAL-EXAMINATION; CLINICAL PALPATION; TUMOR RESPONSE;

D O I：

10.1093/annonc/mdm201

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neoadjuvant (primary systemic) treatment has become a standard option for primary operable disease for patients who are candidates for adjuvant systemic chemotherapy, irrespective of the size of the tumor. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2006 regarding neoadjuvant treatment for operable disease required updating. Therefore, a third international panel of representatives of a number of breast cancer clinical research groups was convened in September 2006 to update these recommendations. As part of this effort, data published to date were critically reviewed and indications for neoadjuvant treatment were newly defined.

引用

页码：1927 / 1934

页数：8

共 73 条

[1]

Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0

[2]

Akashi-Tanaka S, 2001, INT J CANCER, V96, P66, DOI 10.1002/1097-0215(20010220)96:1<66::AID-IJC7>3.0.CO

[3]

2-T

[4] Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy [J].

Akazawa, K ;

Tamaki, Y ;

Taguchi, T ;

Tanji, Y ;

Miyoshi, Y ;

Kim, SJ ;

Ueda, S ;

Yanagisawa, T ;

Sato, Y ;

Tamura, S ;

Noguchi, S .

BREAST JOURNAL, 2006, 12 (02) :130-137

[5] High prognostic significance of residual disease after neoadjuvant chemotherapy:: a retrospective study in 710 patients with operable breast cancer [J].

Amat, S ;

Abrial, C ;

Penault-Llorca, F ;

Delva, R ;

Bougnoux, P ;

Leduc, B ;

Mouret-Reynier, MA ;

Mery-Mignard, D ;

Bleuse, JP ;

Dauplat, J ;

Curé, H ;

Chollet, P .

BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 (03) :255-263

[6] Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer [J].

Ayers, M ;

Symmans, WF ;

Stec, J ;

Damokosh, AI ;

Clark, E ;

Hess, K ;

Lecocke, M ;

Metivier, J ;

Booser, D ;

Ibrahim, N ;

Valero, V ;

Royce, M ;

Arun, B ;

Whitman, G ;

Ross, J ;

Sneige, N ;

Hortobagyi, GN ;

Pusztai, L .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2284-2293

[7] MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy [J].

Belli, P. ;

Costantini, M. ;

Malaspina, C. ;

Magistrelli, A. ;

LaTorre, G. ;

Bonomo, L. .

CLINICAL RADIOLOGY, 2006, 61 (11) :946-953

[8] Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy [J].

Bodini, M ;

Berruti, A ;

Bottini, A ;

Allevi, G ;

Fiorentino, C ;

Brizzi, MP ;

Bersiga, A ;

Generali, D ;

Volpi, D ;

Marini, U ;

Aguggini, S ;

Tampellini, M ;

Alquati, P ;

Olivetti, L ;

Dogliotti, L .

BREAST CANCER RESEARCH AND TREATMENT, 2004, 85 (03) :211-218

[9] Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer - The role of anthrocycline dose intensity [J].

Bozzetti, C ;

Musolino, A ;

Camisa, R ;

Bisagni, G ;

Flora, M ;

Bassano, C ;

Martella, E ;

Lagrasta, C ;

Nizzoli, R ;

Personeni, N ;

Leonardi, F ;

Cocconi, G ;

Ardizzoni, A .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (02) :171-177

[10] Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer [J].

Burcombe, RJ ;

Makris, A ;

Richman, PI ;

Daley, FM ;

Noble, S ;

Pittam, M ;

Wright, D ;

Allen, SA ;

Dove, J ;

Wilson, GD .

BRITISH JOURNAL OF CANCER, 2005, 92 (01) :147-155

← 1 2 3 4 5 6 7 8 →